一名腺苷脱氨酶缺乏-重症联合免疫缺陷患者患伯基特淋巴瘤，接受聚乙二醇化腺苷脱氨酶治疗。
Burkitt's lymphoma in a patient with adenosine deaminase deficiency-severe combined immunodeficiency treated with polyethylene glycol-adenosine deaminase.
作者信息
Husain Maitham, Grunebaum Eyal, Naqvi Ahmed, Atkinson Adelle, Ngan Bo-Yee, Aiuti Alessandro, Roifman Chaim M
机构信息
Division of Immunology/Allergy, The Hospital for Sick Children and The University of Toronto, Toronto, Ontario, Canada.
出版信息
J Pediatr. 2007 Jul;151(1):93-5. doi: 10.1016/j.jpeds.2007.03.059.
We describe a patient with severe combined immunodeficiency because of aberrations in adenosine deaminase (ADA) who despite adequate replacement with polyethylene glycol-linked ADA (PEG-ADA) for 13 years developed Burkitt's lymphoma. Although treatment corrected the metabolic abnormalities caused by ADA deficiency, it failed to fully restore cellular immunity.
我们描述了一名因腺苷脱氨酶（ADA）异常而患有严重联合免疫缺陷的患者，尽管用聚乙二醇连接的ADA（PEG-ADA）进行了13年的充分替代治疗，但仍发生了伯基特淋巴瘤。虽然治疗纠正了由ADA缺乏引起的代谢异常，但未能完全恢复细胞免疫。
Zotero 插件